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1. Introduction
Although incidence has declined in recent years, gastric cancer still represents the second
most frequent cause of cancer-related mortality in the world [1].  The prognosis of stom‐
ach cancer is related to the stage of disease at the time of diagnosis, with a good progno‐
sis associated with early gastric cancer [2]. Therefore, it is essential an early diagnosis of
gastric  carcinoma,  at  present  only about  10-20% of  cancers  being diagnosed in an early
phase [3]. A great interest has arisen in recent years in the detection and management of
premalignant conditions and early gastric cancer because of the high cure rate achieved
treating these lesions, compared with advanced gastric cancer. The well known multistep
cascade of  carcinogenesis  developed by Correa [4]  is  represented by superficial  gastritis
followed  by  atrophic  gastritis,  intestinal  metaplasia  and  increasing  grades  of  dysplasia,
leading to gastric  adenocarcinoma. Surveillance of the premalignant lesions could deter‐
mine an early detection of patients with disease progression, with the possibility of early
therapeutic intervention and improved survival of these patients [5].
Diagnosis and localization of premalignant lesions and early gastric cancer is difficult be‐
cause of the possible lack of evident gross endoscopic signs, even with the performance
of  multiple  random biopsies  [6].  Another  problem with  conventional  white  light  endo‐
scopic diagnosis of these lesions consists in finding the exact location of previously sam‐
pled sites  for  endoscopic  or  surgical  treatment  [7].  Recently  developed new endoscopic
techniques have surpassed some of these drawbacks and have an improved accuracy of
diagnosing early cancers and precancerous lesions.
© 2013 Lazăr et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
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2. Material and methods
In order to evaluate the role of endoscopy and biopsy in assessing preneoplastic gastric le‐
sions, we prospectively included in our study 96 consecutive patients with dyspeptic symp‐
toms, admitted at the Department of Gastroenterology of the County Emergency Hospital
Timisoara, Romania, between April 2010 and March 2011. The patients with various condi‐
tions which prevented satisfactory endoscopic examination were excluded from the study.
Previously, the patients were informed and given their written consent regarding the proto‐
col and the maneuvers of intervention included in the study.
All the endoscopic investigations were performed by senior endoscopists, with a conven‐
tional endoscope of the type Olympus Exera 140 (Japan). According to the criteria of the
Sydney system of endoscopic evaluation of the gastritis [8,9,10], we designed a protocol
(completed for each case) including: location of lesions, endoscopic aspect at the antral and
body level (normal, focal or diffuse erythematous gastritis, erosive gastritis, erosive-hemor‐
rhagic gastritis, atrophic gastritis, petechial gastritis), maintaining of certain particular ele‐
ments (hypertrophy of the folds, nodularity, etc.), the severity of gastritis on endoscopy
(mild, moderate, and severe).
For each case 5 biopsies were taken and processed: two biopsies from the antral level (A1 =
the small curvature; A2 = the large curvature), two biopsies from the gastric body (C1 = the
small curvature; C2 = the large curvature) and a biopsy from the gastric angle (U). More‐
over, all macroscopically visible lesions have been biopsied with specification of their loca‐
tion and clinical diagnosis.
Tissue fragments were processed in the same manner, with fixation in 4% formaldehyde,
paraffin inclusion and stained with hematoxylin-eosin. For histological identification of H.
pylori we utilized the Giemsa modified stain. Histochemical reactions AA-PAS pH 2.5 and
HID-AA allowed to appreciate the profile of mucins on sections examined. Morphological
investigation was performed by a pathologist with experience in digestive pathology.
Statistical analysis of data was performed in a computerized manner, on the folder created,
with specialized programs: Epi Info 6.04, SPSS 10 and Open Epi. This analysis consisted of:
• calculating the arithmetic means and standard deviations, for the quantitative variables;
• calculating the frequencies and percentages for the qualitative variables;
• statistical comparison of percentages with the χ2 (square Chi) test;
• statistical estimation of results was performed using the criteria of decision of statistical
tests:
• p<0.05- significant differences
• p<0.01- very significant differences
• p<0.001- extremely significant differences.
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3. Results
A total of 96 patients (58 females and 38 males) aged between 24 and 86 years (mean age
60.1±15.1 years) were included in the study. Age groups and gender distribution are shown
in Table 1 and Graphic 1.
Age groups Males(no. of cases; %)
Females
(no. of cases; %)
21-30 years 0 (0%) 6 (10.35%)
31-40 years 4 (10.53%) 0 (0%)
41-50 years 6 (15.79%) 12 (20.69%)
51-60 years 6 (15.79%) 8 (13.79%)
61-70 years 8 (21.05%) 20 (34.48%)
≥ 71 years 14 (36.84%) 12 (20.69%)
Total patients 38 (100%) 58 (100%)
Table 1. Age groups and gender distribution of cases

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Graphic 1. Distribution of cases according to age groups and gender
Gastric biopsies (480 samples) were taken and processed from these patients (two antral bi‐
opsies, two biopsies from the body, and one biopsy from the gastric angle for each case).
Atrophic gastritis, defined endoscopically by the appearance of submucosal vessels, giving
rise to a mucosal vascular pattern similar to that found in the colon, sometimes associated
with other features, e.g, mucosal discoloration, smoothness, or flattened rugal folds, consti‐
tuted a rarely encountered entity in our study. In the cases studied we did not observe any
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case of antral atrophic gastritis. In the gastric body, atrophic gastritis, was noted in 6 elderly
patients (Tab 2).
Endoscopic aspect AntrumNo. of cases (%)
Body
No. of cases (%)
Focal erythematous gastritis 12 (12.5 %) 0 (0%)
Diffuse erythematous gastritis 54 (56.1 %) 22 (23%)
Erosive gastritis 4 (4.2 %) 0 (0%)
Erosive-hemorrhagic gastritis 2 (2.1 %) 0 (0%)
Petechial gastritis 22 (23 %) 10 (10.4%)
Atrophic gastritis 0 (0 %) 6 (6.3%)
Normal aspect 2 (2.1 %) 58 (60.3%)
Table 2. Frequency of gastritis diagnosed endoscopically
For this lesion we noted a poor correlation between the conventional endoscopic investiga‐
tion and histopathological examination (Tab. 3).
In accordance with the Sydney system, the morphological criteria of quantification applied
to cases with gastric atrophy are the following:
• 0 = absent;
• 1 = mild (disappearance of less than 25% of glands);
• 2 = moderate (disappearance of 25 - 50% of glands);
• 3 = severe (disappearance of over 50% of glands);
• 4 = biopsy inappropriate for histopathological interpretation.
Age groups
Antral atrophy score
(no. of cases; %)
Gastric body atrophy score
(no. of cases; %)
0 1 2 3 0 1 2 3
21-30 years 6 - - - 6 - - -
31-40 years 2 - 2 - 2 - 2 -
41-50 years 10 2 6 - 8 4 6 -
51-60 years 8 - 6 - 8 2 4 -
61-70 years 20 4 4 - 18 2 8 -
≥ 71 years 4 4 16 2 2 6 14 4
Total patients 50 (52.1%) 10 (10.4%) 34(35.4%) 2 (2.1%) 44 (45.8%) 14 (14.6%) 34 (35.4%) 4 (4.2%)
Table 3. Distribution of the histological score of atrophy identified histopathologically
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Atrophic chronic gastritis is characterized histopathologically by the numeric decrease in
glandular structures of the gastric mucosa and development of new metaplastic glands lined
by intestinal and/or pseudo-pyloric epithelium. We did not consider as real atrophy certain
modifications of the gastric mucosa that produce a false reduction in gastric glands, such as
the massive inflammatory infiltrate or the edema of the lamina propria.
From the total number of cases included in the study, we observed lesions of atrophic type
in 46 antral biopsies (48%) and 52 gastric body biopsies (54.2%).
For antral location (Graphic 2) 10 cases with mild atrophy were noted (21.7%), 34 cases with
moderate atrophy (74%) and 2 cases with severe atrophy (4.3% - Fig. 2). Glandular atrophy
of gastric mucosa was observed much more frequently in patients with older ages (over 61
years). Biopsies noted with score 3 for atrophy pertain only to patients with ages ≥ 71 years.
Glandular atrophy was more frequently encountered in gastric body biopsies (but without
significant differences compared with the antrum, p=0.386), being predominant in patients
with average or old ages. Especially moderate and mild forms of atrophy were noted (14
cases with mild atrophy – 27%; 34 cases with moderate atrophy – 65.4% - Fig. 3; 4 cases with
severe atrophy – 7.6%). All patients with severe glandular atrophy pertain to the age group
≥ 71 years.
Figure 1. Congestive gastritis of gastric body, with mild atrophy of the mucosa
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Figure 2. Antral chronic gastritis with severe atrophy and intestinal metaplasia. HE x 200.
Figure 3. Chronic gastritis of the gastric body with moderate atrophy. HE x 100.














Mild atrophy Moderate atrophy Severe atrophy
Antrum Gastric body
Graphic 2. Histological evaluation of gastric atrophy
Intestinal metaplasia (IM) represents the replacement of the surface and glandular gastric
epithelium by one composed of cells of the intestinal type (small or large intestine).
In conventional endoscopy, modifications such as nodules of yellow and white-nacreous
color, aspect like fish scales or diffuse granular are suggestive for intestinal metaplasia of
gastric mucosa. Such lesions were evident in 7 patients (4 males and 3 females) with ages
between 54 and 76 years, with location in the gastric body.
In histopathological examination, preparations stained through usual morphological meth‐
ods do not allow for the certainty diagnosis, nor do they allow for classification of intestinal
metaplasia. For these reasons we used histochemical stain methods which give exact infor‐
mation on the composition of the mucus synthesized by the modified glands, respectively
the neutral mucins, sialo- and sulfomucins.
Among histochemical methods recommended by the specialty literature, we used staining
methods PAS-AA at pH 2.5 and reaction with colloidal iron diamine-AA (HID-AA).
Type I intestinal metaplasia (complete) is characterized by relatively normal glandular archi‐
tecture, with straight crypts and glands lined by absorbing cells which do not secrete mucus
and goblet cells with flattened nuclei and with widened apical pole, these two cellular types
being encountered in approximately equal proportions. Occasionally, at the base of the
glands one can observe Paneth cells. We identified this form of intestinal metaplasia with
the PAS-AA stain, due to the presence of blue sialomucins in goblet cells (Fig. 4). Reaction
with paraphenyldiamine is negative.
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Figure 4. Type I intestinal metaplasia. AA-PAS x 200.
Type II intestinal metaplasia presents slight architectural modifications, with elongated and
tortuous crypts, with focal areas of foveolar hyperplasia and columnar cells in variable num‐
ber, which contain a mixture of neutral mucines and sialomucins, but not sulfomucins. The
proportion of the goblet cells is greater than in type I. PAS-AA positive reaction is translated
by mixed areas, PAS-positive and alcyanophil, representing neutral and acid mucines. The
positive material is located in the apical portion of epithelial cells, in the lumen of some
glands and in goblet cells (Fig. 5).
Type III of intestinal metaplasia is characterized morphologically by important glandular
distortions, with ramified glands, lined with columnar cells which secrete sulfomucins and
goblet cells secreting sialomucins. PAS reaction is negative, but the HID-AA reaction ap‐
pears intensely positive, through both dyeing solutions. The positive substrate appears in
goblet cells (blue), in the apical portion of columnar cells and in the lumen of metaplastic
glands (dark brown) (Fig. 6 and Fig. 7).
The prevalence of intestinal metaplasia identified histopathologically at the antral level was
of 20.8% (20 cases), and at the level of the gastric body of 25% (24 cases – Tab. 3) (p=0.492).
At the antral level we noted 18 cases with focal distribution (score given 1 and 2) and only
two cases with diffuse distribution (score 3) interesting almost entirely the gastric glandular
epithelium. Following the extension of intestinal metaplasia according to patients’ age, we
observed the great frequency of types II and III in patients over 61 years old. For gastric
body biopsies we did not encountered intestinal metaplasias with score 3, but 18 cases of
metaplasias with score 1 and 6 cases with score 2 were identified. These metaplastic trans‐
formations occur more frequently in older patients, but also in patients from the age groups
31-40 years and 41-50 years (Tab 4).
Gastric Carcinoma- New Insights into Current Management10
Figure 5. Type II intestinal metaplasia. AA-PAS x 200.
Figure 6. Type III intestinal metaplasia. HID-AA x 400.
The Role of Endoscopy and Biopsy in Evaluating Preneoplastic and Particular Gastric Lesions
http://dx.doi.org/10.5772/52676
11
Figure 7. Secretion of sulfomucins (brown) and sialomucins (blue) from intestinal metaplasia type III. HID-AA x 400.
In accordance with the Sydney system, the morphological criteria of quantification applied
to cases with intestinal metaplasia are the following:
• 0 = absent;
• 1 = mild (intestinal metaplasia in a focus of 1-4 glands);
• 2 =moderate (intestinal metaplasia in separate foci, but limited as extension);
• 3 = severe (intestinal metaplasia in over 50% from the gastric epithelium);
• 4 = biopsy inappropriate for histopathological interpretation.
Age groups
IM – antral biopsies
(no. cases; %)
IM – gastric body biopsies
(no. cases; %)
0 1 2 3 0 1 2 3
21-30 years 6 - - 6 - - -
31-40 years 4 - - - 2 - 2 -
41-50 years 18 - - - 16 2 - -
51-60 years 10 4 - - 12 2 - -
61-70 years 24 2 - 2 24 2 2 -
≥ 71 years 14 10 2 - 12 12 2 -
Total patients 76 (79.2%) 16(16.6%) 2 (2.1%) 2 (2.1%) 72 (75%) 18 (18.7%) 6 (6.3%) 0 (0%)
IM –intestinal metaplasia
Table 4. Distribution of the histological score given to intestinal metaplasia
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For both locations, type I intestinal metaplasia was the most frequent encountered type
(11.4% for antral biopsies and 15.6% for gastric body biopsies). The distribution of the three
types of intestinal metaplasia at the antrum and gastric body level, respectively, did not dif‐
fer significantly (p=0.560). Type II of intestinal metaplasia presented a relatively uniform
distribution in all age groups (Tab. 5).
Age groups
IM – antral biopsies IM – gastric body biopsies
I II III I II III
21-30 years - - - - - -
31-40 years - - - - 1 1
41-50 years - - 1 1 -
51-60 years 3 1 - 1 1 -
61-70 years - 3 1 3 - 1
≥ 71 years 8 2 2 10 1 3
Total patients 11 (11.4%) 6 (6.25%) 3 (3.1%) 15 (15.6%) 4 (4.2%) 5 (5.2%)
Table 5. Types of intestinal metaplasia
In our study we evaluated the incidence and types of epithelial dysplasia encountered in
patients with dyspeptic symptoms. In accordance with the Vienna classification, dysplastic
modifications were divided in low-grade dysplasia and high-grade dysplasia.
Histopathological examination of the 96 cases showed dysplastic lesions in 10 patients, prev‐
alence being of 10.4%.
Low-grade dysplasia, observed in 8 patients (Tab. 6, Graphic 3), is characterized by glandu‐
lar architecture mostly preserved, sometimes with the presence of pseudovilli, cystic dilated
glands or slightly irregular glands, with discrete intraluminal papillary projections or serrat‐
ed aspect. Glandular structures are lined with high, crowded cells, with or without mucous
vacuoles at the apical pole. The nuclei appear elongated and pseudostratified, discretely




Low-grade dysplasia High-grade dysplasia
21-30 years - -
31-40 years 1 -
41-50 years - -
51-60 years 1 -
61-70 years 2 1
≥ 71 years 4 1
Total patients 8 (8.33%) 2 (2.1%)
Table 6. Epithelial dysplasia in the cases studied
The Role of Endoscopy and Biopsy in Evaluating Preneoplastic and Particular Gastric Lesions
http://dx.doi.org/10.5772/52676
13































Graphic 3. The distribution of cases with epithelial dysplasia
Figure 8. Low-grade epithelial dysplasia. HE x 100.
In all cases, dysplastic lesions were diagnosed histopathologically in the biopsies taken from the
antrum. From an endoscopic point of view, patients presented more frequently aspects of antral
diffuse erythematous gastritis (in 7 cases). In the case of a 66 year-old patient, the antral mucosa
did not show macroscopic modifications which were visible with conventional gastroscopy. Ep‐
ithelial dysplasia is observed mostly in patients in age groups 51-60 years, 61-70 years, and ≥ 71
years. In the cases studied we noted low-grade dysplastic lesions in a young patient, of age 36.
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Only in 2 patients we noted high-grade dysplastic modifications. High-grade epithelial dys‐
plasia is characterized histopathologically by highly distorted glandular architecture, with
crowded, irregular and ramified glands, with frequent papillary intraluminal projections,
lined with stratified epithelium, with crowded, pleomorphic nuclei overlapping, with in‐
tense mitotic activity, losing of normal polarity, nuclei that touch the apical pole of the cell.
In the neoplastic epithelium, goblet cells and Paneth cells are absent (Fig. 10).
Figure 9. Low-grade epithelial dysplasia (detail). HE x 200.
Figure 10. High-grade epithelial dysplasia. HE x 200.
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These 2 patients were males of 64 and 75 years, respectively. In the case of the 75-year old
patient, pangastritis obvious endoscopically was characterized through aspects of focal er‐
ythematous gastritis of the antrum with mild intensity and petechial gastritis of the gastric
body, of severe intensity. For the second patient, gastroscopy showed only aspects of eryth‐
ematous diffuse antral gastritis with moderate intensity. In both patients, infection with H.
pylori proved to be negative histopathologically.
From the particular lesions  observed, we mention the case of a 79-year old patient who
presented in endoscopic investigation a nodular aspect of the mucosa of the antrum and
gastric body, on the background of a petechial antral gastritis with mild intensity (Fig. 11).
Histopathologically a particular form of pangastritis was diagnosed, granulomatous gastri‐
tis with non-necrotizing granulomas consisting of epitheloid cells and multinuclear cells,
surrounded by lymphocytes, accompanied by a rich inflammatory lymphoplasmocytic in‐
filtrate and atrophic modifications of the mucosa (Fig. 12 and Fig. 13). Lesions were more
intense on the large curvature, for antral biopsy as well as for the biopsy taken from the
gastric  body.  Anamnestic  data  and  other  investigations  performed  excluded  a  possible
sarcoidosis  or  an idiopathic  granulomatous gastritis,  diagnostic  conclusion being that  of
gastric Crohn’s disease.
Figure 11. Congestive gastritis of the gastric body, at the large curvature, with nodular aspect.
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Figure 12. Gastric Crohn’s disease. HE x 200.
Figure 13. Non-necrotizing granulomas in the deep mucosa. HE x 400.
The Role of Endoscopy and Biopsy in Evaluating Preneoplastic and Particular Gastric Lesions
http://dx.doi.org/10.5772/52676
17
Another particular case is that of a patient aged 77, with gastroscopic modifications of diffuse
erythematous gastritis of the antrum, of mild intensity. Although the gastric body did not ap‐
pear modified, histopathological exam showed a rich lymphoplasmocytic infiltrate in the lami‐
na propria, very frequent intraepithelial lymphocytes (at the level of the surface epithelium
and in superficial glands), vacuolizations of epithelial cells, a slight glandular atrophy, discrete
activity and absence of bacterial colonization (Fig. 14 and 15). Histopathological image was
characteristic for lymphocytic gastritis, a rarely encountered form.
Figure 14. Lymphocytic gastritis. HE x 200.
Figure 15. Lymphocytic gastritis. Numerous intraepithelial lymphocytes. HE x 400.
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4. Discussions
For the endoscopists, evaluation the presence or absence of gastritis based on the endoscopic
aspect of the gastric mucosa represents a common practice. Throughout the years, the con‐
cept of “endoscopic gastritis” has gained credibility, its existence being recognized by the
Sydney System of classifying gastritis [8,9,10]. Numerous studies followed the concordance
between endoscopy and histopathological exam regarding the diagnosis of gastritis. The re‐
sults of these works are contradictory, most of them supporting a low degree of concord‐
ance. However, the significant correlation between the gastroscopic and histopathological
aspects in severe forms of gastritis are mentioned, and exclusion of active gastritis in case of
a normal endoscopic aspect [11].
Epidemiological and clinicopathological studies have proved that the extent, the intensity
and the distribution of gastric atrophy and inflammation are closely correlated with the inci‐
dence of gastric cancer [12,13]. Presently, the idea is accepted that only histopathological ex‐
amination of gastric mucosa can correctly assess the risk of neoplastic progression of a
gastric lesion, through identifying the modifications called preneoplastic: atrophy, intestinal
or pyloric metaplasia, epithelial dysplasia [14].
Following the studies performed by Siurala M. in Finland and Estonia [15], Correa P. in Co‐
lumbia and numerous Japanese authors [4], initially separate entities such as superficial
chronic gastritis, atrophy, metaplasia, dysplasia and carcinoma were integrated in a hypo‐
thetical sequence, called “the cascade of Correa” [16]. This hypothesis of gastric carcinogene‐
sis, presented in 1984, was lacking the triggering etiologic element. The discovery in the
same year of H. pylori [17] placed the infection of gastric mucosa with this bacterium on the
first step of the carcinogenesis cascade [18].
Histopathological lesions regarded as preneoplastic are represented by chronic atrophic gas‐
tritis, intestinal metaplasia and dysplasia. In their evolution, these entities can be regarded
as a pyramid with a very wide base, composed of the population infected with H. pylori. A
segment of this population (greater in the developing countries, compared with industrial‐
ized countries) will present the evolution of lesions towards atrophic gastritis, with or with‐
out intestinal metaplasia. Only a small part of the population will develop lesions of
dysplasia and possibly gastric adenocarcinoma. In the cascade of carcinogenesis, the closer a
lesion is of neoplasia, the greater is its risk to progress towards gastric carcinoma [14]. Thus,
chronic gastritis is a remote and uncertain precursor of gastric cancer, which constitutes
rather a predisposing condition. High-grade dysplasia is a true neoplastic lesion [19,20].
Gastric atrophy is defined as a numeric reduction of the self glandular structures of the gas‐
tric mucosa [21,22]. This definition, purely morphological, implies a disappearance of glands
characteristic for an area of the gastric mucosa, for instance specialized glands from the gas‐
tric body, and their replacement either with extracellular matrix, fibroblasts or collagen, or
by intestinal type or pseudopyloric glands. These modifications imply the alteration of
physiological mechanisms, for instance, anomalies of the secretion of mucins and acid.
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Atrophic lesion is defined by the presence of atrophy areas in the gastric mucosa. The most
frequent causes are the long-term infection with H. pylori and autoimmune gastritis. In the
actualized Sydney system, the term of “atrophic gastritis” is used to differentiate this entity
by the “non-atrophic gastritis” or simply “gastritis”, a lesion with severity expressed in the
antrum and identified in most patients infected with H. pylori.
Atrophic gastritis is characterized by the numeric decrease or disappearance of typical gas‐
tric glands, the expansion of antral type mucosa in the gastric body (antralization or pseudo‐
pyloric metaplasia) and areas of intestinal metaplasia. This entity presents a significant
epidemiologic risk for the gastric adenocarcinoma, the prognostic implications being deter‐
mined by the extent and distribution of atrophic areas [14,16,23,24].
Studies from literature have shown that the presence of atrophic gastritis has an annual inci‐
dence of progression to gastric cancer of approximately 0.5-1%, and that the extent of atro‐
phic gastritis within the stomach correlates with the risk of progression to carcinoma [25-28].
The two forms of atrophic gastritis are represented by corporal autoimmune and by multifo‐
cal atrophic gastritis, the later being more common, associated with H. pylori infection, and
with lesions of metaplasia. The presence of infection has been associated with an approxi‐
mately 10-fold increased risk of atrophic gastritis development. There has been demonstrat‐
ed an important regional variation in the prevalence of atrophic gastritis in H. pylori-
infected individuals, with an increase of about 3-fold in Asia, in comparison with Western
countries [29,30].
The pathophysiology associated with the increased risk of gastric cancer in patients with
gastric atrophy may be related to achlorhydria, which predisposes to gastric bacterial over‐
growth, accumulation of N-nitroso compounds, and diminished ascorbate secretion into the
gastric lumen. Moreover, low acid output determines increased serum gastrin levels that
may contribute to abnormal cell growth and increased risk of neoplastic progression [31].
In our study, the endoscopic aspect of atrophic gastritis was rarely encountered. Some au‐
thors signal the reduced percentage of atrophic gastritis cases diagnosed endoscopically, the
lesions being obvious only for the severe forms as intensity [32]. In the cases studied we did
not observe any case of antral atrophic gastritis. In the gastric body, atrophic gastritis, was
noted in 6 elderly patients
For this lesion we noted a poor correlation between the conventional endoscopic investiga‐
tion and histopathological examination. Out of the total number of biopsies included in the
study, we observed lesions of atrophic type in 46 antral biopsies (48%) and 52 biopsies of the
gastric body (54.2%); location of the atrophy was encountered more frequently at the level of
the gastric body, but without statistical significance (p=0.386). Location of the chronic atro‐
phic gastritis predominantly at the level of the gastric body is mentioned in specialty litera‐
ture. This lesion presents a multifocal disposition with individual foci, initially developed at
the level of the gastric angle. The foci extend and merge along the small curvature and on
the anterior and posterior walls of the stomach [27]. In a recent study it is shown that most
gastric carcinomas of intestinal type develop on the background of a wide terrain of atrophic
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gastritis, with small dispersed areas of intestinal metaplasia, which progresses proximally
towards the large gastric curvature [33].
For the antral location we noted 10 cases with mild atrophy (21.7%), 34 cases with moder‐
ate atrophy (74%) and 2 cases with severe atrophy (4.3%). The glandular atrophy of the
gastric mucosa was encountered much more frequently in patients with older ages (over
61 years old). The biopsies graded with score 3 for atrophy pertain only to patients with
ages ≥ 71 year.
Glandular atrophy was encountered more frequently in biopsies of the gastric body, being
predominant in patients with average and old ages. Especially moderate and mild forms of
atrophy were noted (14 cases with mild atrophy – 27%; 34 cases with moderate atrophy –
65.4%; 4 cases with severe atrophy – 7.6%). All patients with severe glandular atrophy per‐
tain to the age group of ≥ 71 years. In concordance with other studies [27,34] we noted an
association between atrophic gastritis, and gastritis in general, predominant in the gastric
body and old age of patients.
Intestinal metaplasia represents the replacement of the gastric lining and glandular epitheli‐
um by one composed of cells of the intestinal type (small or large intestine). Multiple at‐
tempts to classify the various forms of intestinal metaplasia led to a complex terminology,
difficult to apply in the medical practice (complete or incomplete, type 1, 2a and 2b, etc.).
The most used classification is the one proposed by Jass and Filipe, which includes 3 types
of intestinal metaplasias:
• type I intestinal metaplasia (the complete type or of small intestine type) is characterized
by relatively normal glandular architecture, with straight crypts and glands lined with ab‐
sorbent cells non-secreting mucus, with striated plate and goblet cells with flattened nu‐
clei and with widened apical pole, these two cellular types being encountered in
approximately equal proportions. Occasionally, at the base of the glands Paneth cells can
be observed. Goblet cells secrete AA-positive sialomucins. Reaction with paraphenyldia‐
mine is negative;
• type II intestinal metaplasia (the incomplete type or enterocolic type) presents slight ar‐
chitectural modifications, with prolonged and tortuous crypts, with focal areas of foveolar
hyperplasia and columnar cells in variable number, which contain a mixture of neutral
mucines and sialomucins, but not sulfated material. The proportion of goblet cells is
greater than in type I. PAS-AA positive reaction translates through mixed PAS-positive
and alcyanophil areas, representing neutral and acid mucines. The positive material is lo‐
cated in the apical portion of epithelial cells, in the lumen of certain glands and in goblet
cells;
• type III of intestinal metaplasia (the incomplete type or colonic type) is characterized mor‐
phologically through important glandular distortions, with ramified glands, lined with
columnar cells which secrete sulfomucins and goblet cells secreting sialomucins and sul‐
fomucins. PAS reaction is negative, but the HID-AA reaction appears intensely positive,
through both coloring solutions. The positive substrate appears in goblet cells (blue), in
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the apical portion of columnar cells and in the lumen of some metaplastic glands (dark-
brown) [14,27,35].
Currently use classifications take into consideration the presence of Paneth cells (complete
metaplasia) or crescent architecture changings, dedifferentiation, and degree of absence of
Paneth cells (incomplete metaplasia), and also the pattern and type of mucin expression.
Type I metaplasia displays decreased expression of gastric mucins (MUC1, MUC5AC, and
MUC6), and expression of the intestinal mucin MUC2. In type II and III metaplasia gastric
mucins (MUC1, MUC5AC, and MUC6) are coexpressed with MUC2 [36]. However, the use
of immunohistochemistry or other special techniques in order to subtype intestinal metapla‐
sia is not widespread in routine practice.
Another pattern of metaplasia- spasmolytic polypeptide expressing metaplasia (SPEM), has
been described in recent years. This type is characterized by the expression of the TFF2 spas‐
molytic polypeptide that is associated with oxyntic atrophy and usually develops in the gas‐
tric body and fundus. SPEM appears to share some characteristics with pseudopyloric
metaplasia, and has a strong association with chronic infection with Helicobacter pylori and
with gastric cancer. Studies suggests that it may represent another pathway to gastric neo‐
plasia [37].
The presence of type I intestinal metaplasia confers a very low risk of malignant transforma‐
tion. However, type III is considered a true dysplastic lesion
Type I metaplasia does not seems to raise the risk of gastric carcinoma. Numerous studies
have shown that the presence of type II or III intestinal metaplasia is associated with a 20-
fold increased risk of gastric cancer [38-40]. Intestinal metaplasia represents a preneoplastic
lesion for the intestinal type of gastric cancer, 42% of patients with type III intestinal meta‐
plasia developing early gastric cancer within five years of follow-up [41].
It remains unclear whether gastric carcinoma arises from areas of intestinal metaplasia or
whether this lesion represents only a marker for higher cancer risk. The prevalence of intes‐
tinal metaplasia (similar to atrophic gastritis) in H. pylori-infected individuals is higher in
Asia (about 40%) in comparison with Western countries [29,30].
Atrophic gastritis and intestinal metaplasia are often unevenly distributed throughout the
stomach. The updated Sydney System is the most widely accepted for classification of gas‐
tritis and recommends five biopsies, two from the antrum (3 cm from the pylorus, greater
and lesser curvatures), one from the incisura and two from the corpus (one from the lesser
curvature, 4 cm proximal to the incisura, and one from the middle of the greater curvature)
[10]. Although this biopsy protocol generally establishes with accuracy H. pylori status and
chronic gastritis, the number of biopsies is controversial with regard to staging of precancer‐
ous gastric lesions, mainly because of their multifocal disposition [42-44].
For an accurate staging and grading of gastric precancerous conditions, the Guideline of the
European Gastrointestinal Endoscopy recommends at least four non-targeted biopsies of
two topographic sites (at the lesser and greater curvature, from both the antrum and the cor‐
pus) and additional target biopsies of lesions [45].
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Although the updated Sydney system have contributed to a uniform description of preneo‐
plastic lesions, in order to predict gastric cancer risk it has been established OLGA staging
system (operative link for gastritis assessment). This system offers a standardized report of
histopathological data with information about the topography and the extent of the atrophic
changes and subgrouping of patients by gastric cancer risk [46,47]. Gastritis stages (0 to IV)
express increasing extents of atrophy, proved on antral and corpus biopsies. Studies have
allocated a small minority of gastritis patients to stages III and IV, associating this subgroup
of population with a significantly higher cancer risk and thus with endoscopic follow-up
programs [48,49]. Because the OLGA system is based on the severity and extent of atrophy,
which held a low interobserver agreement, it was introduced a modified system-based on
intestinal metaplasia, OLGIM (operative link for gastric intestinal metaplasia), with a high
level of interobserver concordance [50]. Implementation of OLGIM system was associated
with an easier histological assessment and the advantage of including of fewer patients into
the high risk stages, therefore a smaller population for whom endoscopic surveillance
would be needed [51].
The surveillance of premalignant gastric lesions may be important for early detection of gas‐
tric cancer and improved survival. Globally, gastric cancer risk is too low to justify endo‐
scopic follow-up in all patients with atrophic gastritis and intestinal metaplasia. Studies
have shown that cancer risk increases in patients with extensive intragastric lesions
[26,28,52]. The two forms of extensive intestinal metaplasia, the so-called “magenstrasse” or
“transitional zones” distribution (intestinal metaplasia found over the lesser curvature from
cardia to pylorus) and the “diffuse distribution” show an increase risk for cancer (odds ratio
[OR] = 5.7 and 12.2, respectively) [53]. In order to establish the extent of atrophy and intesti‐
nal metaplasia, it can be used endoscopic assessment, histological assessment of multiple bi‐
opsies and serology. Serologic testing for pepsinogens, gastrin and H.pylori antibodies can
establish the extent of atrophic gastritis and identifies patients at increased risk of develop‐
ing gastric cancer [54].
The Guideline of the European Gastrointestinal Endoscopy recommends that endoscopic
surveillance should be offered to patients with extensive atrophy and/or intestinal metapla‐
sia every 3 years after diagnosis [45].
Correct classification of intestinal metaplasia requires performing some relatively sophisti‐
cate histochemical techniques, whose interpretation was not standardized up to present day.
From the histochemical methods recommended by specialty literature, in our study we used
coloration methods PAS-AA at a pH of 2.5 and reaction with colloidal iron diamine-AA
(HID-AA).
In conventional endoscopy, modifications of the type of intestinal metaplasia of gastric mu‐
cosa were evident in 7 patients (4 males and 3 females) with ages between 54 and 76 years,
with location at the level of the gastric body.
The incidence of intestinal metaplasia identified histopathologically at the level of the an‐
trum was of 20.8% (20 cases), and at the level of the gastric body of 25% (24 cases), without
any significant differences between the antral location and the location at the level of the
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gastric body, respectively, of the metaplasia (p=0.492). At the antral level we noted 18 cases
with focal disposition (score given 1 and 2) and only 2 cases with diffuse disposition (score
3), interesting almost entirely the gastric glandular epithelium. Following the extension of
the intestinal metaplasia in relation with patients` age, we observed the great frequency of
types II and III in patients over 61 years old. For the biopsies of the gastric body we did not
note intestinal metaplasias with score 3, but we identified 18 cases of metaplasias with score
1 and 6 cases with score 2. These metaplastic transformations appear more frequently in eld‐
erly patients, but also in patients from the age groups 31-40 years and 41-50 years.
For both locations we remarked the predominance of type I intestinal metaplasia (11.4% for
antral biopsies and15.6% for biopsies of the gastric body, without statistically significant dif‐
ferences between the two locations, p=0.398). Type III was a lesion rarely encountered in our
study, being slightly more frequent in the gastric body (5.2%), in comparison with the an‐
trum (3.1%) and noted especially in patients over the age of 50. Type II intestinal metaplasia
presented a relatively uniform distribution in all age groups. In the large study of Suriani R.
and collaborators [55], which included 1750 patients, type III intestinal metaplasia was not‐
ed in 6.7% of cases, from which 5.7% identified only in the antral mucosa.
Neoplasia  constitutes  the  final  stage  of  phenotypic  and  genetic  progressive  changings
which  affect  the  normal  cellular  morphology,  resulting  in  a  new  cell  characterized
through uncontrolled proliferation and potential  of migrating and implanting. In epithe‐
lial tissues, the first noticeable modification in optical microscopy is the alteration of cell
morphology.  Tumoral  cells  present  large  nuclei,  with  prominent  nucleoli  and  granular
chromatin or  in  rough blocks.  In comparison with the nucleus,  the cytoplasm is  poorly
represented, the nucleus-cytoplasm ratio being much increased. Cytological alterations are
associated with various degrees of architectural anomalies. Such epithelial changings can
appear in two situations: in epithelial injuries, followed by processes of reparation and in
neoplastic alterations. For the first situation the term of reactive atypia is used, and for the
second the term of dysplasia.
Throughout several decades, the pathologists have tried to standardize the criteria of diag‐
nosis and grading for epithelial dysplasia. Pathologists from around the world united their
efforts, but their opinions have coincided only in regard to the epithelial dysplasia of the
mucosa of large intestine and the dysplasia in the Barrett epithelium. The discovery of the
H. pylori bacterium and its relationship with gastric cancer focused the attention of re‐
searchers upon the gastric preneoplastic lesions. It was suggested that the eradication of this
infection can prevent or even reduce the regression of these lesions. Unlike metaplasia or
atrophy, whose types and classifications were established without major disputes, specify‐
ing the definition and diagnosis criteria for dysplasia created significant controversies
among the Western and the Japanese pathologists. Japan represents one of the countries
with the greatest incidences for gastric adenocarcinoma and at the same time, with the best
survival rates in gastric cancer. The reasons invoked for exceptional results are: implement‐
ing the early diagnosis programs, introducing innovating endoscopic techniques and espe‐
cially including some borderline lesions in the group of carcinomas, while other pathologists
include them in the category of dysplasia [14].
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There were differences between Japanese and European/North American pathologists in
categorizing intraepithelial neoplasia; for instance, lesions interpreted by the latter as high-
grade intraepithelial neoplasia (dysplasia) have been frequently classified by Japanese path‐
ologists as “noninvasive intramucosal carcinoma”. In an attempt to resolve this issue,
several proposals have been made regarding terminology of the morphological spectrum of
lesions ranging from non-neoplastic changes to early invasive cancer.
Thus, in order to eliminate the existent dissensions, an international forum was formed, and
in 1996, Schlemper RJ organized a seminar with this topic, the results being published in the
Lancet magazine in 1997 [56]. Subsequently, several study groups were constituted formed
by Japanese pathologists and Western pathologists who made their goal to establish a con‐
sensus on the classification of preneoplastic lesions. One of these classifications, accepted by
the World Health Organization, was presented at the seminar from Padua, Italy in 1998, and
represents a model of histopathological interpretation and of choosing the therapeutic con‐
duit [57,58].
The Padua Model includes the definition of dysplasia as pre-invasive neoplasia and the clas‐
sification of gastric neoplasia in 5 categories:
1. negative for dysplasia;
2. non-defined for dysplasia;
3. non-invasive neoplasia;
4. suspicion of invasive cancer;
5. gastric cancer.
These lesional categories are similar with the lesions included in the Japanese Classification
of the Gastric Cancer. Each category corresponds to one or several sub-categories, in order
to cover the entire spectrum of epithelial alterations [14].
In 1998, on occasion of the World Congress of Gastroenterology in Vienna, a consensus was
reached in regard to the terminology for the gastrointestinal epithelial dysplasia, named
“The VIENNA Classification” [19]. In this classification, the diagnosis of “high-grade dys‐
plasia/adenoma”, “carcinoma in situ (CIS)”, and “suspicion of invasive carcinoma” were
grouped in a single category (category 4), called “high-grade non-invasive neoplasm”, due
to the therapeutic recommendation which was similar for all these sub-groups.
At the beginning of the year 2000, the Vienna classification was reviewed, in category 4 in‐
cluding a new subcategory, namely, the intramucous carcinoma [59]. The terminology of
this consensus makes a distinction between high-grade intraepithelial neoplasia, without the
actual invasion of the lamina propria, and respectively with the invasion of the lamina prop‐
ria, the last term being named intramucous carcinoma at the level of the esophagus and of
the stomach. At the level of the colon, the risk of nodal invasion is null in this situation, for
which reason in the West there is the tendency to avoid the term “carcinoma” for the lesions
without invasion of the submucosa, since they are treated completely only through local ex‐
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cision. Beyond this stage, all neoplastic lesions with invasion of the submucosa are termed
invasive carcinomas.
The Vienna Classification reviewed of gastrointestinal epithelial neoplasia:
Category 1: Negative for dysplasia/neoplasia
Category 2: Non-defined for dysplasia/neoplasia
Category 3: Low-grade epithelial neoplasia:
• low-grade adenoma/dysplasia
Category 4: High-grade epithelial neoplasia:
4.1. High-grade adenoma/dysplasia
4.2. Non-invasive carcinoma (carcinoma „in situ”)
4.3. Suspect of invasive carcinoma
4.4. Intramucous carcinoma
Category 5: Carcinoma with invasion of the submucosa.
At the end of the year 2000 the work Classification of the WHO revised was published, in
which category 4 in the Vienna classification was adopted under the name of “high-grade
intraepithelial neoplasia” and is defined as “modification of the mucosa with cytological
and architectural aspects of malignity without the invasion of the stroma; it includes the le‐
sions of severe dysplasia and carcinoma in situ” [60].
In our study we evaluated the incidence and forms of epithelial dysplasia encountered in
patients with dyspeptic symptoms. In accordance with the Vienna classification, the dys‐
plastic modifications were classified in low-grade dysplasia and high-grade dysplasia.
Current WHO classification [61] considers the following conditions as precursor lesions of
invasive neoplasia (intraepithelial neoplasia) of the stomach:
• gastritis-associated dysplasia:
– adenomatous (type 1)





• fundic gland polyp-associated dysplasia.
According to the WHO classification of tumors of the stomach 2010, the following catego‐
ries of gastric intraepithelial neoplasia (dysplasia) should be considered:
Gastric Carcinoma- New Insights into Current Management26
1. Negative for intraepithelial neoplasia (dysplasia). This subgroup includes benign mucosal
processes that are inflammatory, metaplastic, or reactive in nature.
2. Indefinite for intraepithelial neoplasia (dysplasia). This term is usually used when an ambig‐
uous morphological pattern is encountered, but is not a final diagnosis. This category is
usually used were there is doubt as to whether a lesion is neoplastic or non-neoplastic
(i.e. reactive or regenerative), particularly in small biopsies exhibiting inflammation.
The dilemma is usually solved by cutting deeper levels, by obtaining additional biop‐
sies, or after treating for possible etiologies.
3. Intraepithelial neoplasia (dysplasia). This category includes epithelial neoplastic prolifera‐
tion characterized by variable cellular and architectural atypia, but without convincing
evidence of invasive growth. Intraepithelial neoplasia (gastric epithelial dysplasia) can
have polypoid, flat or slightly depressed growth patterns. The flat or slightly depressed
patterns may show an irregular appearance on chromoendoscopy or microvasculature
anomalies on narrow-band imaging, aspects that are not apparent with conventional
white-light endoscopy. In the western countries, the term “adenoma” has been applied
when the neoplastic proliferation produces a protruding lesion. By contrast, in Japan,
“adenomas” include all gross types (flat, elevated and depressed).
In  the  stomach,  most  cases  of  dysplasia  have  an  intestinal  phenotype  (adenomatous;
type  I)  resembling  colonic  adenomas  with  crowded,  tubular  glands  lined  by  atypical
columnar  cells;  the  cells  present  overlapping,  hyperchromatic  and/or  pleomorphic  nu‐
clei,  with  pseudostratification  and inconspicuous  nucleoli,  mucin  depletion,  and lack  of
surface maturation [62].
The other variant is represented by the gastric phenotype (foveolar or pyloric phenotype;
type II) in which the cells are cuboidal or low-columnar, with clear or eosinophilic cyto‐
plasm, and round to oval nuclei [62].
These two variants may be differentiated by expression of mucin, CD10, and CDX2, as well
as by background changes in the gastric mucosa. The intestinal/adenomatous type expresses
MUC2, CD10, and CDX2, and the gastric/foveolar type expresses MUC5AC, the absence of
CD10 and low positivity of CDX2 [63,64]. Intraepithelial neoplasia (dysplasia) is stratified
into two grades, low or high.
5. Intramucosal invasive neoplasia/intramucosal carcinoma
This category defines carcinomas invading lamina propria and that are distinguished from
intraepithelial neoplasia by desmoplastic changes that can be minimal or absent, and also by
marked glandular crowding, excessive branching, and budding.
The diagnosis of intramucosal carcinoma indicates that there is an increased risk of lym‐
phatic invasion and lymph-node metastasis. Novel endoscopic techniques can allow treat‐
ment of some of these patients without open surgery, particularly for lesions of < 2 cm in
size and for those that are well-differentiated [65].




This category defines carcinomas that show invasion beyond lamina propria. In the stom‐
ach, this diagnosis is associated with a varying risk of nodal and distant metastasis and
overall prognosis. The recommended treatment consists in surgical resection, sometimes
with neoadjuvant therapy.
Histopathological examination of the 96 cases showed dysplastic lesions in 10 patients, the
incidence being of only 10.4%. According to the data in the literature, the prevalence of dys‐
plasia varies between 0.5 - 4% in Western countries and between 9-20% in areas with high
risk for gastric cancer [66]. The high frequency of epithelial dysplasia, observed in our
study, can also be explained through the modality of taking the biopsies for each case (the
large number of biopsies/case, the different location of taking the sample), method of work
that eliminates somehow the errors connected with the focal, dispersed characteristic of dys‐
plastic lesions.
Low-grade dysplasia, encountered in 8 patients, is characterized by glandular architecture
mostly preserved, sometimes with the presence of pseudovilli, cystically dilated glands or
slightly irregular glands, with discrete intraluminal papillary projections or serrated aspect.
Glandular structures are lined with high, crowded cells, with or without mucous vacuoles.
The nuclei, discretely pleomorphic, appear elongated and pseudostratified, situated in the
inferior half of the cytoplasm. The mitotic activity is discrete.
In all cases, dysplastic lesions were diagnosed histopathologically at the level of the biopsies
taken from the antrum. In literature the predominantly antral location of premalignant gas‐
tric lesions is mentioned, except for the atrophic gastritis associated with pernicious anemia,
which is identified especially at the level of the gastric body [27].
Epithelial dysplasia is encountered especially in patients over 51 years old. In the cases stud‐
ied we encountered dysplastic lesions of low grade in a young 36-year-old patient.
Data reveal that low-grade dysplasia may regress in up to 60% of cases, and progress to
high-grade dysplasia in 10-20% of cases [67,68]. High-grade dysplasia rarely regresses, being
associated with an annual incidence of progression to carcinoma of 2-6%; it can be uni- or
multifocal, and it is often associated with synchronous cancer. A prospective study from the
Netherlands has shown that high-grade dysplasia was associated with a markedly increased
risk of progression to carcinoma (adjusted hazard ratio, 40.1) [5,69].
While routine surveillance for Barrett’s esophagus is recommended and guidelines for the
surveillance for other gastrointestinal premalignant conditions are available [70,71], in the
last years the management for gastric premalignant conditions varied from surgery to annu‐
al surveillance for dysplasia and from no treatment to surveillance every 3 to 5 years for less
advanced lesions [72-75]. Data showed that endoscopic mucosal resection and routine sur‐
veillance of advanced premalignant gastric lesions may significantly decrease the mortality
and morbidity associated with gastric cancer. Yeh and collaborators [76] have elaborated a
simulation model of gastric cancer natural history for a cohort of U.S. men with a recent inci‐
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dental diagnosis of gastric precancerous lesions, and they estimated that among 50-year old
men with dysplasia, approximately one in every twenty will develop gastric cancer in their
lifetime, which is similar to the risk of colorectal cancer in the like-aged general U.S popula‐
tion or persons with Barrett’s esophagus. This study highlighted that EMR with surveillance
every 1 to 5 years for dysplasia is promising for secondary cancer prevention because it can
reduce gastric cancer risk by 90%, and it is considered cost-effective in the U.S. Endoscopic
surveillance of less advanced lesions does not appear to be cost-effective, except possibly
immigrants from high-risk countries.
The Guideline of the European Gastrointestinal Endoscopy [45] recommends that patients
with low grade dysplasia, in the absence of an endoscopically defined lesion, should receive
follow-up within 1 year after diagnosis. If there is an endoscopically visible lesion, endo‐
scopic resection should be considered in order to obtain a more accurate diagnosis. For pa‐
tients with high grade dysplasia, if there are no endoscopically defined lesions, endoscopic
reassessment with extensive biopsy sampling and surveillance at 6-month to 1-year intervals
is recommended. In the case of endoscopically defined lesions, resection needs to be consid‐
ered, either through endoscopy (endoscopic mucosal resection) or surgery.
From an endoscopic point of view, the patients presented more frequently aspects of an‐
tral diffuse erythematous gastritis (in 7 cases). In the case of a 66-year old patient, the an‐
tral mucosa did not show visible macroscopic modifications on conventional endoscopy.
Though the  quality  of  the  images  obtained through standard endoscopy was  improved
substantially in the past few decades, the modifications observed during conventional en‐
doscopy are correlated in a smaller measure with the histopathologicaldiagnosis of atro‐
phic  gastritis,  intestinal  metaplasia  and  dysplasia.  These  results  are  due  to  the
unsatisfactory viewing of the structure of the mucosa, its color and vascularization, impor‐
tant elements in the differential diagnosis between premalignant lesions and incipient gas‐
tric cancer [27]. So, data show that conventional white light endoscopy cannot accurately
diagnose premalignant gastric  lesions.  Magnification endoscopy and narrow band imag‐
ing (NBI), with or without magnification, improve the diagnosis of these conditions [45].
Some  studies  concluded  that  correlation  between  white  light  endoscopy  and  histology
was poor [77]. Absence of rugae and presence of visible vessels in the gastric mucosa can
predict  severe atrophy but with a low sensitivity [78].  Intestinal  metaplasia may appear
endoscopically as  thin,  white  mucosal  deposits,  but  the value of  some endoscopic signs
for its diagnosis it is still unclear [79]. In addition to low accuracy, the lesions detected on
conventional  endoscopy were associated also with low reproducibility [80,81].  Therefore
current data show that white light endoscopy cannot be relied upon to accurately diag‐
nose patients with atrophy and intestinal metaplasia.
Recent studies have followed the performances of endoscopy by magnification in the detec‐
tion of premalignant gastric lesions. The correlation between the endoscopic aspects and his‐
topathological diagnosis proved to be exceptional [82-84]. Detailed visualization of the
superficial gastric mucosa allows classifying the patterns that the gastric folds and foveoles
can take in different pathological conditions. The model of superficial micro-vascularization
identifies the chronic gastritis induced by H. pylori and other entities classified as preneo‐
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plastic. In H. pylori positive gastritis, collector venules lose their regular aspect, “sea star”-
like, in some cases being invisible. In atrophic gastritis, the alterations in the subepithelial
capillary network and of the collector venules are correlated with the degree of atrophy. The
areas of intestinal metaplasia are suspected in the presence of depressions with wide and
elongated epithelial rigs, separated by deep grooves [83]. Data show that high resolution
magnifying endoscopy appears superior to standard endoscopy, allowing accuracy for the
diagnosis of H. pylori gastritis, intestinal metaplasia and dysplasia [85,86].
The techniques of in vivo coloration represent adjuvant methods for the optimal viewing of
the lesions during the conventional endoscopy, or with magnification. Methylene blue visu‐
alizes the areas of intestinal metaplasia. Architectural modifications from the neoplastic
areas are emphasized by using the indigo carmine solution. Unlike conventional endoscopy,
chromoendoscopy can identify limited foci of incipient gastric carcinoma [32,87]. Studies
suggest that chromoendoscopy, particularly with magnification, helps to identify lesions of
intestinal metaplasia and dysplasia. Dinis-Ribeiro et al. proposed a chromoendoscopy classi‐
fication with methylene blue for these lesions that proved to be reproducible and highly ac‐
curate [87]. The use of other solutions, such as indigo carmine, acetic acid, or hematoxylin,
has shown a high diagnostic accuracy, especially for dysplasia [88,89].
No comparative study of magnification with or without chromoendoscopy has been made,
despite the fact that Tanaka et al [89] have suggested that magnification chromoendoscopy
with acetic acid is superior to conventional magnification endoscopy and indigo carmine
chromoendoscopy.
However, magnification chromoendoscopy lengthens the time of the endoscopic procedure
and may compromise patient tolerance. For these reasons, performance of this technique
should be restricted to experienced centers [45].
In the last years new endoscopic techniques were introduced, which utilize certain spectral
features of the light, for instance image obtained through narrow band, autofluorescence or
fluorescence capturing. The results of implementing this new methods of investigation are
only preliminary and in some studies even conflicting, thus their follow-up on long periods
of time is necessary [27].
The technique of narrow band imaging (NBI) has been found to have good sensitivity and
specificity for the diagnosis of gastric lesions [90-95]. The principle of this new method is
based on modification of the spectral characteristics of the optical filter in the light source,
leading to improved visibility of mucosal components. With the use of NBI in combination
with image magnification, mucosal structures are highlighted with accuracy, because of the
increased contrast between surface and vascular pattern [96]. The study of Capelle et al [97]
provides evidence that NBI yields more accurate results in the surveillance of patients with
intestinal metaplasia and dysplasia than conventional endoscopy. They have shown that
considerably more lesions of intestinal metaplasia were detected by NBI compared to white
light endoscopy and that the sensitivity for the detection of advanced premalignant gastric
lesions increased by 20-71% for NBI.
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Both NBI and chromoendoscopy can reveal the mucosal pattern and microvascular struc‐
ture of the mucosa that have been considered as distinctive characteristics of early gastric
cancer and premalignant gastric lesions. The study of Zhang et al [98] showed that the im‐
age quality of magnifying NBI is superior to magnifying conventional endoscopy in respect
of morphology, pit pattern and blood capillary form of abnormal gastric zones, but also to
magnifying chromoendoscopy concerning blood capillary form.
Angiogenesis represents an important element in gastric carcinogenesis [99], the vascular
pattern of gastric cancer and precancerous lesions being differ from that of normal mucosa
[100]. Nakayoshi et al [101] studied 165 patients with early gastric cancer with magnifying
NBI, showing that 66.1% of differentiated adenocarcinoma had fine microvascular networks,
and 85.7% of undifferentiated carcinoma had corkscrew microvascular networks.
The use of auto-fluorescence endoscopy demonstrated a high correlation between Barrett’s
esophagus and histological diagnosis, but the correlation between gastric cancer and this
method is still controversial [102,103].
Confocal endomicroscopy is an endoscopic technique that produces 1000-fold magnifica‐
tion cross-sectional images and can accurately diagnose the presence of early cancer in tar‐
geted  areas.  A  recent  gastric  pit-pattern  classification  for  assessment  of  gastritis  and
atrophy showed a high correlation with histological changing and needs further evalua‐
tion [104,105]. This technique is too elaborate to be used for assessment of the entire gas‐
tric mucosa.
Liu et al [106] studied the microvascular architecture of early gastric cancer with confocal
microscopy, and revealed that differentiated gastric cancerous mucosa presented hypervas‐
cularity and microvessels of different caliber and shapes, and undifferentiated gastric cancer
showed hypovascularity and irregular short branched vessels.
Only in 2 patients we observed high-grade dysplastic modifications. High-grade epithelial
dysplasia is characterized histopathologically through intensely distorted glandular archi‐
tecture, with crowded glands, irregular and ramified, with frequent intraluminal papillary
projections, lined with stratified epithelium, with crowded and overlapping nuclei, pleio‐
morphic, with intense mitotic activity, loss of normal polarity, nuclei that touch the apical
pole of the cell. In the neoplastic epithelium, goblet cells and Paneth cells are absent.
The patients diagnosed histopathologically with high-grade epithelial dysplasia were both
males, with ages of 64 and 75 years, respectively. In the case of the 75-year old patient, the
pangastritis evident endoscopically was characterized by aspects of focal erythematous gas‐
tritis of the antrum with mild intensity and petechial gastritis of the gastric body, of severe
intensity. For the second patient, gastroscopy showed only aspects of antral diffuse eryth‐
ematous gastritis with moderate intensity. In both patients, the infection with H. pylori
proved negative histopathologically.




For the diagnoses of atrophy we noted a poor correlation between the conventional endo‐
scopic investigation and histopathological examination. Type I intestinal metaplasia predo‐
minated both for antrum and gastric body. Type III intestinal metaplasia was encountered
slightly more frequent at the level of gastric body, especially in patients over 50 years old.
About 2% of patients presented high-grade dysplasia needing resection treatment. The use
of modern endoscopic techniques may help identifying gastric precancerous lesions. Among
our study group, we found some rare types of gastritis, such as gastric Crohn’s disease and
lymphocytic gastritis, emphasizing the importance of performing multiple biopsies for an
accurate histopathological diagnosis of gastritis.
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